Physician profile
Thomas Mann
NPI 1457308447
$3,610.36
in general payments reported to CMS, 2019-2025
14 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $131 · 2021: $232 · 2022: $52.26 · 2023: $1,064 · 2024: $831 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273 · Travel and Lodging: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.84 |
| Travel and Lodging | $870.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gemini Mountain Medical, LLC | $1,388.83 | 2019-2024 | |
| Depuy Synthes Sales INC. | $717.89 | 2020-2025 | Dynacord, Fms, Rigidloop |
| Shoulder Innovations, INC. | $709.48 | 2023 | Inset System |
| Arthrex, INC. | $238.36 | 2024 | |
| Qt Imaging, INC. | $146.65 | 2021 | |
| Vericel Corporation | $100.11 | 2021-2025 | Maci |
| Horizon Therapeutics Plc | $64.11 | 2019-2022 | |
| Stryker Corporation | $61.05 | 2021-2023 | Inspace |
| Bioventus LLC | $45.50 | 2021-2025 | Durolane |
| Smith+Nephew, INC. | $38.83 | 2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Pacira Therapeutics, INC. | $38.14 | 2019-2020 | |
| Ossur Americas, INC. | $30.83 | 2024 | Miami J |
| Breg, INC | $16.46 | 2023 | Breg Vpulse, Plasmaflow, Polarcarewave |
| Arthrosurface Incorporated | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.